Medivation’s Dimebon Flunks Ph3 for Huntington’s Disease

Once considered a potential ALS drug, Dimebon suffers another dismal failure in a Phase 3 clinical trial for Huntington’s Disease patients, failing to meet the primary and all secondary endpoints in the latest trial. Medivation, is perservering with its belief in Dimebon and is continuing its remaining Phase 3 trial for AD.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail